Literature DB >> 25413587

Characterization of the cell of origin and propagation potential of the fibroblast growth factor 9-induced mouse model of lung adenocarcinoma.

Daisuke Arai1, Ahmed E Hegab1, Kenzo Soejima1, Aoi Kuroda1, Kota Ishioka1, Hiroyuki Yasuda1, Katsuhiko Naoki1, Kagawa Shizuko1, Junko Hamamoto1, Yongjun Yin2, David M Ornitz2, Tomoko Betsuyaku1.   

Abstract

Fibroblast growth factor 9 (FGF9) is essential for lung development and is highly expressed in a subset of human lung adenocarcinomas. We recently described a mouse model in which FGF9 expression in the lung epithelium caused proliferation of the airway epithelium at the terminal bronchioles and led to rapid development of adenocarcinoma. Here, we used this model to characterize the effects of prolonged FGF9 induction on the proximal and distal lung epithelia, and examined the propagation potential of FGF9-induced lung tumours. We showed that prolonged FGF9 over-expression in the lung resulted in the development of adenocarcinomas arising from both alveolar type II and airway secretory cells in the lung parenchyma and airways, respectively. We found that tumour cells harboured tumour-propagating cells that were able to form secondary tumours in recipient mice, regardless of FGF9 expression. However, the highest degree of tumour propagation was observed when unfractionated tumour cells were co-administered with autologous, tumour-associated mesenchymal cells. Although the initiation of lung adenocarcinomas was dependent on activation of the FGF9-FGF receptor 3 (FGFR3) signalling axis, maintenance and propagation of the tumour was independent of this signalling. Activation of an alternative FGF-FGFR axis and the interaction with tumour stromal cells is likely to be responsible for the development of this independence. This study demonstrates the complex role of FGF-FGFR signalling in the initiation, growth and propagation of lung cancer. Our findings suggest that analysing the expressions of FGF-FGFRs in human lung cancer will be a useful tool for guiding customized therapy.
Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  FGF9; FGFR; adenocarcinoma; lung cancer; tumour propagation; tumour-associated lung fibroblasts

Mesh:

Substances:

Year:  2014        PMID: 25413587      PMCID: PMC4329097          DOI: 10.1002/path.4486

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  44 in total

1.  Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

Authors:  Miguel Taron; Yukito Ichinose; Rafael Rosell; Tony Mok; Bartomeu Massuti; Lurdes Zamora; Jose Luis Mate; Christian Manegold; Mayumi Ono; Cristina Queralt; Thierry Jahan; Jose Javier Sanchez; Maria Sanchez-Ronco; Victor Hsue; David Jablons; Jose Miguel Sanchez; Teresa Moran
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

2.  Identification of bronchioalveolar stem cells in normal lung and lung cancer.

Authors:  Carla F Bender Kim; Erica L Jackson; Amber E Woolfenden; Sharon Lawrence; Imran Babar; Sinae Vogel; Denise Crowley; Roderick T Bronson; Tyler Jacks
Journal:  Cell       Date:  2005-06-17       Impact factor: 41.582

3.  TGF-β signaling in stromal cells acts upstream of FGF-10 to regulate epithelial stem cell growth in the adult lung.

Authors:  Jonathan L McQualter; Rosa C McCarty; Joanne Van der Velden; Robert J J O'Donoghue; Marie-Liesse Asselin-Labat; Steven Bozinovski; Ivan Bertoncello
Journal:  Stem Cell Res       Date:  2013-08-28       Impact factor: 2.020

4.  Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer.

Authors:  Keiko Ohgino; Kenzo Soejima; Hiroyuki Yasuda; Yuichiro Hayashi; Junko Hamamoto; Katsuhiko Naoki; Daisuke Arai; Kota Ishioka; Takashi Sato; Hideki Terai; Shinnosuke Ikemura; Satoshi Yoda; Tetsuo Tani; Aoi Kuroda; Tomoko Betsuyaku
Journal:  Lung Cancer       Date:  2013-10-30       Impact factor: 5.705

5.  Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: A role for the FGF-2/FGFR-2 axis.

Authors:  Sebastián Giulianelli; Juan P Cerliani; Caroline A Lamb; Victoria T Fabris; María C Bottino; María A Gorostiaga; Virginia Novaro; Adrián Góngora; Alberto Baldi; Alfredo Molinolo; Claudia Lanari
Journal:  Int J Cancer       Date:  2008-12-01       Impact factor: 7.396

6.  Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

Authors:  Marcin Imielinski; Alice H Berger; Peter S Hammerman; Bryan Hernandez; Trevor J Pugh; Eran Hodis; Jeonghee Cho; James Suh; Marzia Capelletti; Andrey Sivachenko; Carrie Sougnez; Daniel Auclair; Michael S Lawrence; Petar Stojanov; Kristian Cibulskis; Kyusam Choi; Luc de Waal; Tanaz Sharifnia; Angela Brooks; Heidi Greulich; Shantanu Banerji; Thomas Zander; Danila Seidel; Frauke Leenders; Sascha Ansén; Corinna Ludwig; Walburga Engel-Riedel; Erich Stoelben; Jürgen Wolf; Chandra Goparju; Kristin Thompson; Wendy Winckler; David Kwiatkowski; Bruce E Johnson; Pasi A Jänne; Vincent A Miller; William Pao; William D Travis; Harvey I Pass; Stacey B Gabriel; Eric S Lander; Roman K Thomas; Levi A Garraway; Gad Getz; Matthew Meyerson
Journal:  Cell       Date:  2012-09-14       Impact factor: 41.582

7.  Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.

Authors:  Danan Li; Takeshi Shimamura; Hongbin Ji; Liang Chen; Henry J Haringsma; Kate McNamara; Mei-Chih Liang; Samanthi A Perera; Sara Zaghlul; Christa L Borgman; Shigeto Kubo; Masaya Takahashi; Yanping Sun; Lucian R Chirieac; Robert F Padera; Neal I Lindeman; Pasi A Jänne; Roman K Thomas; Matthew L Meyerson; Michael J Eck; Jeffrey A Engelman; Geoffrey I Shapiro; Kwok-Kin Wong
Journal:  Cancer Cell       Date:  2007-07       Impact factor: 31.743

Review 8.  Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis.

Authors:  Jie Li; Oluwole Fadare; Li Xiang; Beihua Kong; Wenxin Zheng
Journal:  J Hematol Oncol       Date:  2012-03-09       Impact factor: 17.388

Review 9.  Tumour heterogeneity and cancer cell plasticity.

Authors:  Corbin E Meacham; Sean J Morrison
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

10.  A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.

Authors:  K E Ware; T K Hinz; E Kleczko; K R Singleton; L A Marek; B A Helfrich; C T Cummings; D K Graham; D Astling; A-C Tan; L E Heasley
Journal:  Oncogenesis       Date:  2013-03-25       Impact factor: 7.485

View more
  8 in total

1.  FGF9/FGFR2 increase cell proliferation by activating ERK1/2, Rb/E2F1, and cell cycle pathways in mouse Leydig tumor cells.

Authors:  Ming-Min Chang; Meng-Shao Lai; Siou-Ying Hong; Bo-Syong Pan; Hsin Huang; Shang-Hsun Yang; Chia-Ching Wu; H Sunny Sun; Jih-Ing Chuang; Chia-Yih Wang; Bu-Miin Huang
Journal:  Cancer Sci       Date:  2018-10-23       Impact factor: 6.716

2.  The Kinome of Human Alveolar Type II and Basal Cells, and Its Reprogramming in Lung Cancer.

Authors:  Sonia M Leach; Jay Finigan; Vihas T Vasu; Rangnath Mishra; Moumita Ghosh; Daniel Foster; Robert Mason; Beata Kosmider; Eveline Farias Hesson; Jeffrey A Kern
Journal:  Am J Respir Cell Mol Biol       Date:  2019-10       Impact factor: 6.914

3.  Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer.

Authors:  Ahmed E Hegab; Naofumi Kameyama; Aoi Kuroda; Shizuko Kagawa; Yongjun Yin; David Ornitz; Tomoko Betsuyaku
Journal:  J Vis Exp       Date:  2016-05-20       Impact factor: 1.355

4.  Pulmonary fibrosis requires cell-autonomous mesenchymal fibroblast growth factor (FGF) signaling.

Authors:  Robert D Guzy; Ling Li; Craig Smith; Samuel J Dorry; Hyun Young Koo; Lin Chen; David M Ornitz
Journal:  J Biol Chem       Date:  2017-05-09       Impact factor: 5.486

Review 5.  The Fibroblast Growth Factor signaling pathway.

Authors:  David M Ornitz; Nobuyuki Itoh
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2015-03-13       Impact factor: 5.814

6.  Inhibition of fibroblast growth factor receptor 3-dependent lung adenocarcinoma with a human monoclonal antibody.

Authors:  Yongjun Yin; Xiaodi Ren; Craig Smith; Qianxu Guo; Maria Malabunga; Ilhem Guernah; Yiwei Zhang; Juqun Shen; Haijun Sun; Nabil Chehab; Nick Loizos; Dale L Ludwig; David M Ornitz
Journal:  Dis Model Mech       Date:  2016-04-07       Impact factor: 5.758

7.  Drug-sensitive FGFR3 mutations in lung adenocarcinoma.

Authors:  P Chandrani; K Prabhash; R Prasad; V Sethunath; M Ranjan; P Iyer; J Aich; H Dhamne; D N Iyer; P Upadhyay; B Mohanty; P Chandna; R Kumar; A Joshi; V Noronha; V Patil; A Ramaswamy; A Karpe; R Thorat; P Chaudhari; A Ingle; A Choughule; A Dutt
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

8.  An FGFR1-SPRY2 Signaling Axis Limits Basal Cell Proliferation in the Steady-State Airway Epithelium.

Authors:  Gayan I Balasooriya; Jo-Anne Johnson; M Albert Basson; Emma L Rawlins
Journal:  Dev Cell       Date:  2016-04-04       Impact factor: 12.270

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.